Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider Paul Silva Purchases 3,680 Shares

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director Paul Silva purchased 3,680 shares of the company’s stock in a transaction that occurred on Thursday, October 22nd. The stock was acquired at an average cost of $27.07 per share, for a total transaction of $99,617.60. Following the transaction, the director owned 3,680 shares in the company, valued at $99,617.60. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Rapport Therapeutics Stock Up 5.9%

RAPP stock traded up $1.47 during mid-day trading on Thursday, reaching $26.53. 1,453,606 shares of the company traded hands, compared to its average volume of 407,078. The firm’s 50 day moving average price is $39.86 and its 200 day moving average price is $39.07. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -8.73 and a beta of 1.22. Rapport Therapeutics, Inc. has a fifty-two week low of $23.75 and a fifty-two week high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.07). On average, analysts anticipate that Rapport Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Key Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 is advancing to Phase 3. Rapport said the drug met both Phase 2 endpoints in bipolar mania, producing statistically significant placebo-adjusted improvements in manic symptoms and overall illness severity. The results strengthen the potential value of RAP-219 and expand its development opportunity beyond epilepsy. Rapport plans Phase III bipolar mania trials
• Positive Sentiment: Analysts continue to raise or maintain bullish targets. JonesTrading increased its price target from $50 to $82 and maintained a Buy rating. BTIG Research also raised its target, while HC Wainwright reaffirmed its Buy rating. Raymond James recently set an $86 target and maintained Strong Buy. The analyst activity suggests Wall Street sees substantial upside if RAP-219 succeeds in later-stage development. BTIG Research price target update HC Wainwright rating update
• Positive Sentiment: CFO Troy Ignelzi bought 5,500 shares for $143,550. The purchase increased his direct holdings by 55% to 15,500 shares, a potentially supportive signal of management confidence. SEC insider ownership filing
• Neutral Sentiment: The clinical results move RAP-219 toward Phase 3 but do not eliminate biotechnology risks, including trial execution, regulatory approval, funding needs, and eventual commercialization.
• Negative Sentiment: Some coverage characterized the trial outcome as narrower than investors initially hoped. Rapport also remains unprofitable, recently reporting quarterly EPS below consensus, which could limit gains if future clinical or financial results disappoint. Rapport bipolar data analysis

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on RAPP shares. TD Cowen reiterated a “buy” rating on shares of Rapport Therapeutics in a report on Tuesday. Leerink Partners began coverage on shares of Rapport Therapeutics in a report on Wednesday, June 24th. They set an “outperform” rating and a $52.00 price objective on the stock. Raymond James Financial reiterated a “strong-buy” rating and issued a $86.00 target price on shares of Rapport Therapeutics in a research note on Tuesday. Wolfe Research started coverage on shares of Rapport Therapeutics in a report on Thursday, October 15th. They issued an “outperform” rating and a $50.00 target price for the company. Finally, Wall Street Zen downgraded shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Rapport Therapeutics has a consensus rating of “Buy” and a consensus target price of $68.36.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. TRV GP V LLC bought a new position in Rapport Therapeutics in the 2nd quarter valued at $261,709,477. ARCH Venture Management LLC bought a new stake in shares of Rapport Therapeutics during the 2nd quarter worth $155,376,512. BlackRock Inc. bought a new stake in shares of Rapport Therapeutics during the 2nd quarter worth $112,500,000. Johnson & Johnson bought a new stake in shares of Rapport Therapeutics during the 2nd quarter worth $74,360,823. Finally, TRV GP VI LLC purchased a new position in shares of Rapport Therapeutics in the 2nd quarter worth about $40,387,314.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.